Antifungal agents, WO2009025733

Area of Science:

• Mycology
• Natural Product Chemistry
• Pharmacology

Background:

• Serious mycoses represent a significant global public health challenge, contributing to morbidity and mortality, particularly in immunocompromised individuals.
• The development of novel antifungal agents is crucial for managing these infections.
• This patent focuses on natural products with potential antifungal properties.

Purpose of the Study:

• To isolate and characterize novel isoxazolidinone-containing natural products from newly identified fungal strains.
• To evaluate the antifungal activity of these isolated compounds against mammalian and plant fungal pathogens.
• To explore potential synergistic effects with existing antifungal agents.

Main Methods:

• Isolation and purification of two novel isoxazolidinone-containing compounds from fungal cultures.
• Structural elucidation of the isolated natural products, noting partial similarity to secalonic acid.
• In vitro and in vivo assessment of antifungal efficacy in mammalian and plant models.
• Investigation of synergistic interactions with other antifungal compounds.

Main Results:

• Successful isolation and characterization of a pure mixture of two novel isoxazolidinone-containing compounds.
• Demonstrated potent antifungal activity against a range of fungal pathogens affecting mammals and plants.
• Observed synergistic effects when combined with other active antifungal ingredients.
• Compounds possess a partial structure related to secalonic acid.

Conclusions:

• The isolation of novel antifungal compounds with a unique mode of action represents a significant advancement.
• These isoxazolidinone-containing molecules show promise as lead compounds for the development of new antifungal therapies.
• Further preclinical and clinical studies are warranted to explore their therapeutic potential.